Consistently, silencing CCL2 also only moderately reduced the LN-metastatic capability of vector-control bladder cancer cells (from 31.25% reduced to 18.75%) but remarkably inhibited the LN-metastatic capability of LNMAT1-overexpressing cells (from 81.25 to 12.50%; Fig. 4l, m and Supplementary Fig. 6d). Here, DUXAP9 is linked to urinary bladder carcinoma.